Immune dysregulation in primary immune thrombocytopenia patients

Figures & data

Table 1. Baseline characteristics of patients with ITP and controls.

	New diagnosed (n=64)	Relapsed (n=60)	Healthy controls
Age	44.69 ± 18.57	40.65 ± 18.65	41.24 ± 11.28
Sex(male/female)	23/41	18/42	14/31
Platelet, ×10^9/l	21.69 ± 19.44*	12.70 ± 9.93*	203.25 ± 22.52
Hemorrhagic symptoms	56/64	55/60	0/45
Splenomegaly	0/64	0/60	0/45
Hepatomegaly	0/64	0/60	0/45

*P<0.05 compared with healthy controls.

Table 2. Proportion of cell subsets in new diagnosed ITP, relapsed ITP and healthy controls.

	New diagnosed	Relapsed	Healthy controls
CD3,% (Within lymphocyte gate)	77.18 ± 11.99	77.82 ± 9.42	75.36 ± 8.27
CD4,% (Within CD3^+ T cell gate)	46.12 ± 12.72^###	42.01 ± 12.01	38.77 ± 6.24
CD8,% (Within CD3^+ T cell gate)	28.08 ± 9.27*^#	31.45 ± 9.25	31.69 ± 4.99
CD4/CD8 ratio	1.90 ± 1.02*^###	1.53 ± 0.83^#	1.25 ± 0.29
B cell, % (Within lymphocyte gate)	3.84 ± 2.15	4.55 ± 3.10	4.39 ± 2.11
NK cell, % (Within lymphocyte gate)	9.05 ± 5.53^###	10.96 ± 5.97^#	14.64 ± 7.24
Treg cell, % (Within CD4^+ T cell gate)	4.20 ± 1.64^###	4.44 ± 1.58^###	5.58 ± 1.20

*P<0.05 compared with the relapsed group.

^###P<0.001 compared with healthy controls.

^#P<0.05 compared with healthy controls.

Table 3. Cell subsets in ‘effective’ and ‘ineffective’ group before treatment.

	Effective	Ineffective	P-value
Age	39.65 ± 19.80	38.85 ± 21.68	0.547
Sex(male/female)	19/50	4/10	0.937
Platelet, ×10^9/l	12.38 ± 9.56	13.21 ± 12.21	0.777
CD3,% (Within lymphocyte gate)	76.77 ± 12.15	76.60 ± 11.23	0.963
CD4,% (Within CD3^+ T cell gate)	43.33 ± 12.20	37.89 ± 15.14	0.148
CD8,% (Within CD3^+ T cell gate)	30.12 ± 8.60	34.92 ± 12.08	0.176
CD4/CD8 ratio	1.60 ± 0.88	1.41 ± 1.03	0.486
B cell, % (Within lymphocyte gate)	4.20 ± 2.31	2.95 ± 2.42	0.123
NK cell, % (Within lymphocyte gate)	8.72 ± 4.72	11.32 ± 8.05	0.326
Treg cell, % (Within CD4^+ T cell gate)	4.61 ± 1.59	5.02 ± 1.99	0.428

Figure 1. CD4/CD8 ratio, CD4+Treg cells, NK cells and B cells in ‘effective’ and ‘ineffective’ group after treatment. (A) CD4/CD8 ratio in ‘ineffective’ group, ‘effective’ group, healthy controls were 2.23 ± 1.10, 1.39 ± 0.80 and 1.25 ± 0.29, respectively. (B) The proportion of CD4+Treg cells (within CD4+ T cell gate) in ‘ineffective’ group, ‘effective’ group, healthy controls were 5.16 ± 1.92, 7.26 ± 2.23 and 5.21 ± 1.17, respectively. (C) The proportion of NK cells (within lymphocyte gate) in ‘ineffective’ group, ‘effective’ group, healthy controls were 6.36 ± 4.54, 7.05 ± 5.42 and 14.15 ± 5.42, respectively. (D) The proportion of B cells (within lymphocyte gate) in ‘ineffective’ group, ‘effective’ group, healthy controls were 3.77 ± 2.75, 5.08 ± 3.16 and 4.40 ± 1.94, respectively.

Figure 2. Pre- and post-treatment immune state in ‘effective’ and ‘ineffective’ group. (A) CD4/CD8 ratio, proportion of CD4+Treg cell, NK cell and B cell in ‘effective’ group (n=10). (B) CD4/CD8 ratio, proportion of CD4+Treg cell, NK cell and B cell in ‘ineffective’ group (n=5).